Drug Profile
Bacteroides thetaiotaomicron - 4D Pharma
Alternative Names: CJRB 203; MRx 1233; ThetanixLatest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator GT Biologics
- Developer 4D Pharma PLC
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Immunomodulators; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Crohn's disease
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 18 Jan 2024 Bacteroides thetaiotaomicron is still in phase I trial for Crohn's disease (In adolescents) in United Kingdom (PO) (CJ Bioscience pipeline, January 2024)
- 18 Jan 2024 Bacteroides thetaiotaomicron is still in preclinical trials for Inflammatory-bowel-diseases in United Kingdom (PO) (CJ Bioscience pipeline, January 2024)
- 05 Oct 2021 Bacteroides thetaiotaomicron is still in phase I trials for Crohn’s disease in United Kingdom (4D pharma pipeline, October 2021)